Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohortTalha Munir, Paolo Ghia, Boo Messahel et al.|Future Oncology|2025Cited by 0